TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
The FDA throws out the company’s second attempt at an accelerated approval.